Profile data is unavailable for this security.
About the company
Bonesupport Holding AB is a Sweden-based orthobiologics company. It develops and commercialize injectable bioceramic bone graft substitutes which remodel to host bone and have the capability to elute drugs directly into the bone void. The marketed synthetic bone graft substitutes are CERAMENT BVF, CERAMENT G and CERAMENT V, which are based on the CERAMENT technology platform. The products are commercially available in Europe and the United States, as well as in India, Malaysia, Oman and Singapore. The products are developed to treat patients with fractures and bone voids caused by trauma and related surgery, as well as caused by infection or diseases, such as chronic osteomyelitis, revision arthroplasty and infected diabetic foot.
- Revenue in SEK (TTM)814.46m
- Net income in SEK90.58m
- Incorporated2010
- Employees131.00
- LocationBonesupport Holding ABScheelevagen 19LUND 223 70SwedenSWE
- Phone+46 462865370
- Fax+46 462865371
- Websitehttps://www.bonesupport.com
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Swedencare AB (publ) | 2.47bn | 76.20m | 7.35bn | 559.00 | 96.40 | 0.9564 | 18.82 | 2.97 | 0.4801 | 0.4801 | 15.58 | 48.39 | 0.2428 | 2.26 | 8.69 | 5,087,037.00 | 0.7483 | 1.38 | 0.7727 | 1.43 | 56.76 | 55.34 | 3.08 | 5.10 | 1.67 | 2.42 | 0.1726 | 45.33 | 27.48 | 88.16 | -37.96 | 20.24 | 30.90 | -- |
| BioGaia AB | 1.36bn | 336.82m | 10.31bn | 222.00 | 31.73 | 6.61 | 25.27 | 7.61 | 3.33 | 3.33 | 13.42 | 16.01 | 0.6442 | -- | -- | 6,455,538.00 | 16.00 | 15.47 | 17.73 | 16.93 | 73.59 | 73.30 | 24.85 | 27.70 | -- | -- | 0.00 | 104.42 | 17.44 | 11.81 | -2.25 | 11.20 | 29.27 | 28.10 |
| Vimian Group AB | 4.05bn | 2.94m | 22.59bn | 1.10k | 8,834.69 | 2.97 | 57.36 | 5.58 | 0.0049 | 0.0049 | 8.25 | 14.67 | 0.3401 | 2.85 | 6.75 | 3,678,284.00 | 0.0938 | -- | 0.1025 | -- | 46.88 | -- | 0.2758 | -- | 2.18 | 2.06 | 0.2734 | -- | 17.92 | -- | 245.95 | -- | -- | -- |
| Bonesupport Holding AB | 814.46m | 90.58m | 23.69bn | 131.00 | 264.20 | 36.29 | 234.31 | 29.09 | 1.36 | 1.36 | 12.29 | 9.92 | 1.16 | 0.6138 | 5.62 | 7,756,762.00 | 12.85 | -9.08 | 14.98 | -11.28 | 92.43 | 90.25 | 11.12 | -11.65 | 3.50 | -- | 0.0222 | -- | 79.76 | 43.65 | 459.44 | -- | 18.39 | -- |
| Bavarian Nordic A/S | 9.36bn | 1.72bn | 24.12bn | 1.61k | 13.82 | 1.45 | 9.09 | 2.58 | 14.36 | 14.36 | 78.05 | 136.86 | 0.4439 | 1.47 | 5.52 | 4,401,443.00 | 8.18 | 1.21 | 10.46 | 1.48 | 52.38 | 53.72 | 18.43 | 4.06 | 0.976 | -- | 0.0106 | 0.00 | 124.14 | 69.78 | 524.66 | -- | 35.76 | -- |
| Camurus AB | 1.69bn | 266.21m | 33.70bn | 249.00 | 128.79 | 10.83 | 119.83 | 19.95 | 4.45 | 4.45 | 28.86 | 52.92 | 0.6246 | 1.03 | 5.83 | 7,929,653.00 | 9.84 | -1.13 | 11.34 | -1.41 | 92.38 | 90.05 | 15.76 | -1.63 | 7.91 | -- | 0.0059 | -- | 79.52 | 103.39 | 676.63 | -- | 16.29 | -- |
| ALK-Abello A/S | 8.30bn | 1.21bn | 49.51bn | 2.80k | 44.12 | 6.90 | 29.43 | 5.96 | 3.59 | 3.59 | 24.40 | 22.97 | 0.7849 | 1.29 | 6.39 | 1,906,162.00 | 11.45 | 3.50 | 13.84 | 4.37 | 63.94 | 60.66 | 14.58 | 5.07 | 1.47 | 32.26 | 0.0911 | 0.00 | 6.94 | 10.60 | 45.07 | -- | 16.32 | -- |
| Orion Oyj | 16.43bn | 3.82bn | 73.28bn | 3.82k | 19.19 | 6.87 | 16.29 | 4.46 | 2.36 | 2.36 | 10.16 | 6.58 | 0.9593 | 1.53 | 6.94 | 393,502.20 | 22.25 | 19.47 | 28.25 | 24.16 | 59.89 | 59.38 | 23.19 | 20.71 | 1.41 | 143.69 | 0.2174 | 91.83 | -11.26 | 4.01 | -37.97 | 1.89 | 11.82 | 1.55 |
| Swedish Orphan Biovitrum AB (publ) | 25.44bn | 3.51bn | 103.24bn | 1.81k | 28.83 | 2.68 | 14.34 | 4.06 | 10.06 | 10.06 | 72.98 | 108.01 | 0.3443 | 1.37 | 5.72 | 14,353,840.00 | 4.75 | 5.93 | 5.85 | 7.60 | 78.60 | 77.42 | 13.81 | 16.61 | 0.6225 | 4.35 | 0.325 | 0.00 | 17.74 | 19.34 | -8.68 | -0.0729 | 53.61 | -- |
Data as of Nov 25 2024. Currency figures normalised to Bonesupport Holding AB's reporting currency: Swedish Krona SEK
39.29%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Swedbank Robur Fonder ABas of 31 Oct 2024 | 6.45m | 9.81% |
| Capital Research & Management Co. (World Investors)as of 31 Dec 2023 | 5.14m | 7.81% |
| Handelsbanken Fonder ABas of 31 Oct 2024 | 2.68m | 4.07% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 2.22m | 3.38% |
| Fj�rde AP-fondenas of 31 Dec 2023 | 2.08m | 3.16% |
| JPMorgan Asset Management (UK) Ltd.as of 31 Oct 2024 | 1.63m | 2.48% |
| Andra AP-fondenas of 29 Aug 2023 | 1.45m | 2.20% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 1.44m | 2.19% |
| Tredje AP-fondenas of 31 Dec 2023 | 1.43m | 2.18% |
| Lancelot Asset Management ABas of 30 Jun 2023 | 1.33m | 2.01% |
More ▼
Data from 30 Jun 2023 - 30 Sep 2024Source: FactSet Research Systems Inc.
